To test if reducing PIP5K1A to dampen oncogenic KRAS signaling could enhance the antineoplastic effect of trametinib, the aforementioned panel of KRAS-mutant, HRAS-mutant, and NRAS-mutant human cancer cell lines in which PIP5K1A expression was unaltered or reduced were treated with or without trametinib. Here, NRAS is linked to cancer.